The following stories appear in full on Today's Vidyya Medical News Service Web site.
With the American College of Cardiology's annual meeting getting ready to get underway this weekend in Orlando, Florida, the results of many clinical trials will be made public. One of the studies, to be discussed at the meeting is the ADMIT study, which found that niacin with Simvastatin can decrease cardiac events in diabetics. Vidyya has the information regarding the study and the prescribing information for the niacins used in the study in today's issue.
To date, medical guidelines have not recommended the use of niacin for the treatment of high cholesterol and triglycerides in diabetics because of concerns about the potential adverse effect on glycemic control. In September 2000, the American Medical Association published results of an Arterial Disease Multiple Intervention Trial (ADMIT) sub-study, which concluded that lipid-modifying doses of niacin have a minimal impact on glucose levels and can be safely prescribed for patients with diabetes as an alternative when statins or fibrates are inadequate or not tolerated.
For more information: Simvastatin, Niacor ® Reduce Cardiac Events By 70% In Landmark Study
Slo-Niacin® is a member of the vitamin B-complex group (nicotinic acid, vitamin B-3) and is suggested as a dietary supplement. This product has the advantage of a slower release of niacin than conventional dosage forms. This may permit its use by those who do not tolerate immediate-release tablets.
Niacin tablets in conjunction with Simvastatin show promise as a preventive against cardiovascular events.
For more information: Prescribing Information: Slo-Niacin ® Polygel ® Controlled-Release Niacin
The ADMIT study found that use of immediate-release Niacor ® helped reduce total cholesterol by 4%, LDL ("bad") cholesterol by 8% and triglycerides by 23%, while increasing HDL cholesterol levels by 29% -- with minimal impact on glycemic control. Niacin use resulted in a small but statistically significant increase in average glucose levels in participants with diabetes. The dropout rate for niacin therapy was similar for both diabetic and non-diabetic patients, with dropout rates of 23% and 16% respectively. Get the prescribing information for Niacor in today's issue of Vidyya.
For more information: Prescribing Information: Niacor ®
Today's Vidyya articles are:
As always, we hope you enjoy the issue.